Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576592 | 0.88 | MEN1 (0.38) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL2989785 | 0.83 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL11813613 | 0.83 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL6335488 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL9198299 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL7533743 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL10679266 | 0.81 | MEN1 (0.35) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL5369982 | 0.80 | MEN1 (0.34) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL1004656 | 0.80 | KDM4C (0.36) | MEN1KMT2AKDM4CGRM5L3MBTL1 | |
| SCHEMBL21437122 | 0.80 | MEN1 (0.37) | MEN1KMT2AKDM4CGRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | claimed |
| JP-2010521465-A | — | — | 2010-06-24 | — | — | JP | claimed |
| EP-2125027-A2 | DE NOVO SYNTHESIS OF CONJUGATES | Nektar Therapeutics (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008112286-A9 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS AL CORP (US) | 2008-12-18 | — | — | WO | claimed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | MEN1 2662/4885KMT2A 2362/4885KDM4C 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.